QbD Based Formulation Development and Optimisation of Ozenoxacin Topical Nano-Emulgel and Efficacy Evaluation Using Impetigo Mice Model

• Published in: AAPS PharmSciTech Vol. 25; no. 5; p. 90
• Main Authors: Ramireddy, Amarnath Reddy, Behara, Dilip Kumar
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 22.04.2024
• Subjects: Administration, Topical; Aminopyridines - administration & dosage; Aminopyridines - chemistry; Aminopyridines - pharmacokinetics; Aminopyridines - pharmacology; Animals; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - chemistry; Anti-Bacterial Agents - pharmacology; Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Chemistry, Pharmaceutical - methods; Disease Models, Animal; Drug Compounding - methods; Emulsions - chemistry; Excipients - chemistry; Gels - chemistry; Impetigo - drug therapy; Mice; Microbial Sensitivity Tests - methods; Nanoparticles - chemistry; Novel Skin Drug Delivery Technology; Pharmacology/Toxicology; Pharmacy; Quinolones - administration & dosage; Quinolones - chemistry; Quinolones - pharmacokinetics; Quinolones - pharmacology; Research Article; Skin - drug effects; Skin - metabolism; Skin Absorption - drug effects; Viscosity; quality by design; anti-bacterial activity; nano-emulgel; box–behnken design; ozenoxacin; in-vivo anti-bacterial activity
• ISSN: 1530-9932; 1530-9932
• DOI: 10.1208/s12249-024-02805-x

To formulate and optimize Ozenoxacin nano-emulsion using Quality by Design (QbD) concept by means of Box–Behnken Design (BBD) and converting it to a gel to form Ozenoxacin nano-emulgel followed by physico-chemical, in-vitro , ex-vivo and in-vivo evaluation. This study demonstrates the application of QbD methodology for the development and optimization of an effective topical nanoemulgel formulation for the treatment of Impetigo focusing on the selection of appropriate excipients, optimization of formulation and process variables, and characterization of critical quality attributes. BBD was used to study the effect of “% of oil, % of S mix and homogenization speed” on critical quality attributes “globule size and % entrapment efficiency” for the optimisation of Ozenoxacin Nano-emulsion. Ozenoxacin loaded nano-emulgel was characterized for “description, identification, pH, specific gravity, amplitude sweep, viscosity, assay, organic impurities, antimicrobial effectiveness testing, in-vitro release testing, ex-vivo permeation testing, skin retention and in-vivo anti-bacterial activity”. In-vitro release and ex-vivo permeation, skin retention and in-vivo anti-bacterial activity were found to be significantly (p < 0.01) higher for the nano-emulgel formulation compared to the innovator formulation (OZANEX™). Antimicrobial effectiveness testing was performed and found that even at 70% label claim of benzoic acid is effective to inhibit microbial growth in the drug product. The systematic application of QbD principles facilitated the successful development and optimization of a Ozenoxacin Nano-Emulsion. Optimised Ozenoxacin Nano-Emulgel can be considered as an effective alternative and found to be stable at least for 6 months at 40 °C / 75% RH and 30 °C / 75% RH. Graphical Abstract